FDA approves Nexium for treatment of teens

Share this article:
The FDA this week cleared AstraZeneca to market its heartburn treatment Nexium to children ages 12 through 17 for the treatment of gastroesophageal reflux disease. Nexium had global sales of $4.6 billion in 2005, making it the fifth best-selling drug in the world. The drug was approved for use in adults in February 2001.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.